Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in hypermutated breast cancer Trial
NCT03492918Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Mar 2022
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in breast cancer, sponsored by Yonsei University. Primary endpoint: Objective Response Rate. Started Mar 2022; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03492918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492918.